<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005824</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-020</org_study_id>
    <secondary_id>CDR0000067835</secondary_id>
    <nct_id>NCT00005824</nct_id>
  </id_info>
  <brief_title>Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma</brief_title>
  <official_title>Pilot Study of the Safety and Feasibility of Autologous Peripheral Blood Stem Cell Transplantation for Patients With Relapsed AIDS-Related Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Malignancy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Malignancy Consortium</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to&#xD;
      give higher doses of chemotherapy drugs and kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of chemotherapy followed by peripheral&#xD;
      stem cell transplantation in treating patients who have recurrent or refractory AIDS-related&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and tolerability of intensive chemotherapy and autologous&#xD;
           peripheral blood stem cell transplantation in patients with recurrent or refractory&#xD;
           AIDS-related lymphoma.&#xD;
&#xD;
        -  Determine the response and response duration in these patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the effect of this treatment regimen on HIV RNA and CD4 cells in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: Patients receive mobilization chemotherapy consisting of cyclophosphamide IV over 2&#xD;
      hours followed 2 days later by daily filgrastim (G-CSF) subcutaneously (SC) until blood&#xD;
      counts recover. Patients then undergo leukopheresis to collect CD34+ cells.&#xD;
&#xD;
      Patients receive conditioning chemotherapy consisting of oral busulfan every 6 hours on days&#xD;
      -7, -6, -5, and -4 for a total of 14 doses and cyclophosphamide IV over 1 hour on days -3 and&#xD;
      -2. Patients undergo autologous stem cell infusion on day 0. G-CSF is administered IV or SC&#xD;
      daily beginning on day 1 and continuing until blood counts recover.&#xD;
&#xD;
      Patients are followed monthly for 1 year and then every 6 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 5-25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Intermediate- or high-grade non-Hodgkin's lymphoma or Hodgkin's disease&#xD;
&#xD;
               -  Failed to achieve complete remission with initial therapy OR&#xD;
&#xD;
               -  Relapsed after initial therapy&#xD;
&#xD;
          -  May be in complete remission after salvage therapy&#xD;
&#xD;
          -  Sensitive to most recent chemotherapy&#xD;
&#xD;
               -  Improvement of at least 25% in bidimensional tumor measurements OR&#xD;
&#xD;
               -  Improvement in evaluable disease sustained over 4 weeks&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  HIV-1 positive&#xD;
&#xD;
          -  CD4 greater than 50 cells/mm^3 (unless not receiving optimal antiretroviral therapy)&#xD;
&#xD;
          -  HIV RNA less than 110,000 copies/mL (unless not receiving optimal antiretroviral&#xD;
             therapy)&#xD;
&#xD;
          -  No active leptomeningeal or parenchymal CNS involvement NOTE: A new classification&#xD;
             scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of&#xD;
             &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former terminology of &quot;low&quot;,&#xD;
             &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the former&#xD;
             terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Physiologic 18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  AST no greater than 3 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL (unless receiving indinavir)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No history of cardiac disease&#xD;
&#xD;
          -  LVEF at least 45%&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No history of symptomatic pulmonary disease&#xD;
&#xD;
          -  DLCO at least 60%&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active opportunistic infections&#xD;
&#xD;
          -  No cytomegalovirus retinitis or pneumonitis requiring maintenance therapy&#xD;
&#xD;
          -  No sensitivity to E. coli-derived products&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 week since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Chronic suppressive therapy for infection allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David T. Scadden, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ, Aboulafia DM, Scadden DT. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66. doi: 10.1016/j.bbmt.2007.03.014.</citation>
    <PMID>18158962</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related diffuse large cell lymphoma</keyword>
  <keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
  <keyword>AIDS-related small noncleaved cell lymphoma</keyword>
  <keyword>HIV-associated Hodgkin lymphoma</keyword>
  <keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
  <keyword>AIDS-related diffuse small cleaved cell lymphoma</keyword>
  <keyword>AIDS-related lymphoblastic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, AIDS-Related</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

